First-line use of encorafenib and binimetinib in BRAF V600E NSCLC recorded a median overall survival of 47.6 months, according to data presented at the ESMO congress. | Read More in JPost.com – The Jerusalem Post – All News from the Middle East, Israel, and the Jewish World
Smotrich calls for IDF chief’s dismissal over feud, argues Trump ‘would have fired him in a call’Smotrich calls for IDF chief’s dismissal over feud, argues Trump ‘would have fired him in a call’
Erdogan praises pope’s ‘astute stance’ on Palestinian issue
Jewish group urges halt to ‘Nakba’ exhibit at Canadian Museum of Human Rights
Woman arrested for alleged yearlong stalking of Israeli model Bar Refaeli
Washington IDF attaché nominee suspected of serious security breach amid Katz-Zamir rift
IDF strikes Hezbollah targets in Lebanon; intensifies West Bank counterterror sweep
Haredi draft exemption bill circulated ahead of Knesset hearings: ‘With God’s help, we’ll succeed’
First year of ceasefire: 370 terrorists eliminated, 1200 targeted operations conducted
The Islamists’ Trojan horse
Almog Cohen reveals: ‘Ben-Gvir hasn’t spoken to me in nearly a year’
Bismuth reveals: This is what the Draft Law will look likeSmotrich calls for IDF chief’s dismissal over feud, argues Trump ‘would have fired him in a call’Smotrich calls for IDF chief’s dismissal over feud, argues Trump ‘would have fired him in a call’
Hashomer Hachadash Youth’s November Conference Opens with Volunteer WorkErdogan praises pope’s ‘astute stance’ on Palestinian issue
Mekorot Reports Net Profit of Approximately NIS 232 Million for the First Nine Months of 2025